When used in combination with cryolipolysis, it can prolong the effect of cryolipolysis by inhibiting fat regeneration
What This Means Clinically For patients who have tried GLP-1 medications and experienced significant side effects, or who are not candidates for appetite-suppressing approaches, AOD 9604 represents a mechanistically different option
Liraglutide is the first drug in this class approved by the FDA and is considered the predecessor to new GLP-1 medications
Focus on week-over-week trends rather than day-to-day changes
Sources: Neelakantan et al., Biochem Pharmacol 2018 | Dimet-Wiley et al., Sci Rep 2024 Security Profile & Chemical Identity Molecular specifications and preclinical safety data 5-Amino-1MQ Chemical Identity A small molecule derived from quinolinium salts, developed at the University of Texas (2017) 5-Amino-1MQ Tolerance & Status Safety data from preclinical studies (DIO mouse model) Published Preclinical Data 3 key studies published in Biochemical Pharmacology and Scientific Reports 35% Reduction of white adipose tissue in 11 days (20 mg/kg, 3 times/day) Physical Effects (11 days) + 40 % Improvement of grip strength in aged mice (22-24 months) Strength & Performance (aged mice) microbiome The combination of 5-Amino-1MQ + caloric restriction establishes a distinct gut microbial profile Protocol & Results Important Notice Search Only Not intended for human consumption
You have your chronological age (years lived) and biological age (cellular and systemic health)
